Research suggests Pirtobrutinib may provide a ... - CLL Support

CLL Support

23,253 members39,948 posts

Research suggests Pirtobrutinib may provide a safe and manageable risk of bleeding in those requiring antithrombotic therapy

3 Replies

You need to be a member of this community to see this post.

Read more about...
3 Replies

You need to be a member of this community to see hidden responses.

Not what you're looking for?

You may also like...

YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'

In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
CLLerinOz profile image
Administrator

BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies

Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Jm954 profile image
Administrator

Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD

Advances in Targeted Therapy for R/R CLL (These OncLive presentations are intended for medical...
lankisterguy profile image
Volunteer

BTK inhibitor challenges by Dr. Nicole Lamanna

Nicole Lamanna, MD, continues her discussion on BTK inhibitor challenges....
lankisterguy profile image
Volunteer

Moderation team

See all
Newdawn profile image
NewdawnAdministrator
Jm954 profile image
Jm954Administrator
AussieNeil profile image
AussieNeilAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.